Synairgen (LON:SNG) Trading Down 16.2% – Time to Sell?

Synairgen plc (LON:SNG)’s stock price traded down 16.2% during mid-day trading on Monday . The company traded as low as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01). Approximately 345,628 shares were traded during trading, a decline of 77% from the average session volume of 1,477,761 shares. The stock had previously closed at GBX 0.84 ($0.01).

Synairgen Stock Down 10.8 %

The stock has a market capitalization of £8.29 million, a P/E ratio of -0.51 and a beta of -2.23. The firm’s 50-day simple moving average is GBX 1.69 and its 200 day simple moving average is GBX 3.05.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).